Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

5.67EUR
20 Jul 2018
Change (% chg)

€0.17 (+3.09%)
Prev Close
€5.50
Open
€5.47
Day's High
€5.88
Day's Low
€5.45
Volume
216,037
Avg. Vol
79,783
52-wk High
€7.63
52-wk Low
€2.91

Latest Key Developments (Source: Significant Developments)

Biofrontera AG Subsidiary Files Suit Against Dusa Pharmaceuticals, Inc
Thursday, 12 Jul 2018 

July 12 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA AG SUBSIDIARY FILES SUIT AGAINST DUSA PHARMACEUTICALS, INC.  Full Article

Sun Pharmaceutical Unit Files Lawsuit Against Biofrontera For Patent Infringement
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Biofrontera AG ::SUN PHARMACEUTICAL INDUSTRIES LTD - CO'S UNIT, DUSA PHARMACEUTICALS FILES LAWSUIT AGAINST BIOFRONTERA FOR PATENT INFRINGEMENT.SUN PHARMACEUTICAL INDUSTRIES - LAWSUIT ALLEGES PATENT INFRINGEMENT OF DUSA'S PATENTS, US 9,723,991 AND US 8,216,289.  Full Article

Biofrontera And Maruho Consider Continuing Collaboration Under New Agreement
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: PHASE 1 OF COLLABORATION BETWEEN BIOFRONTERA AND MARUHO COMPLETED.BIOFRONTERA AND MARUHO CURRENTLY CONSIDER CONTINUING THEIR COLLABORATION UNDER A NEW AGREEMENT.  Full Article

Biofrontera Will Be Completing A Voluntary Review Of The February 2018 Share Issuance
Friday, 6 Jul 2018 

July 6 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA AG WILL BE COMPLETING A VOLUNTARY REVIEW OF THE FEBRUARY 2018 SHARE ISSUANCE.PROVIDED CLARIFICATION IN RESPECT TO ALLEGATIONS MADE BY DEUTSCHE BALATON AG.DISMISSES ALLEGATIONS IN THEIR ENTIRETY.BIOFRONTERA - DECIDED TODAY TO OBTAIN OPINION OF AN UNBIASED SUBJECT-MATTER EXPERT IN ORDER TO COUNTER ACCUSATIONS MADE BY DEUTSCHE BALATON AG.  Full Article

Biofrontera H1 Total Revenue In Range Of EUR 8.9 And 9.1 Million
Thursday, 5 Jul 2018 

July 5 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: SALES REVENUE FOR AMELUZ(R) DOUBLED FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2018.TOTAL REVENUE OF BIOFRONTERA AG FOR PERIOD JANUARY 1 TO JUNE 30 WAS IN RANGE OF EUR 8.9 AND 9.1 MILLION.CONFIRMS CURRENT REVENUE GUIDANCE OF EUR 16 TO 20 MILLION FOR FULL YEAR.CONTINUES TO EXPECT A SIGNIFICANT INCREASE IN REVENUE FOR SECOND HALF OF 2018.BIOFRONTERA - SIX-MONTH PRODUCT SALES IN USA ARE EXPECTED AT APPROX EUR 6.4 MILLION, COMPARED TO EUR 2.4 MILLION IN SAME PERIOD IN 2017.BIOFRONTERA - PRODUCT SALES IN EUROPE ARE ESTIMATED TO BE APPROX EUR 2.4 MILLION, COMPARED TO EUR 1.8 MILLION IN FIRST 6 MONTHS OF 2017.  Full Article

Biofrontera: Deutsche Balaton Launches Tender Offer For Up To 6.25 Mln Biofrontera Shares
Wednesday, 30 May 2018 

May 30 (Reuters) - Biofrontera AG ::TENDER OFFER FOR UP TO 6,250,000 BIOFRONTERA SHARES.BIOFRONTERA - DEUTSCHE BALATON BIOTECH COMMENCED UNSOLICITED EXCHANGE OFFER TO ACQUIRE UP TO 6,250,000 OF COMPANY'S SHARES.SHAREHOLDERS ARE STRONGLY ADVISED TO TAKE NO ACTION IN RELATION TO OFFER AT THIS TIME PENDING REVIEW OF OFFER BY CO'S MANAGEMENT AND SUPERVISORY BOARDS.  Full Article

Biofrontera FY Revenues Up 96% At EUR 12.0 Million
Monday, 30 Apr 2018 

April 30 (Reuters) - Biofrontera AG ::REVENUES INCREASED 96% TO EUR12.0 MILLION FOR FULL YEAR 2017,.GROSS PROFIT INCREASED 130% TO EUR10.3 MILLION FOR FULL YEAR 2017,.NET LOSS WAS EUR16.1 MILLION IN 2017, COMPARED TO LOSS OF EUR 10.6 MILLION IN SAME PERIOD 2016.  Full Article

Deltus 30. AG To Make Offer For Stake In Biofrontera AG
Wednesday, 25 Apr 2018 

April 25 (Reuters) - DELTUS 30. AG::SAYS TO MAKE OFFER FOR UP TO 6.25 MILLION SHARES IN BIOFRONTERA AG.SAYS HAS NO INTENTION OF GAINING CONTROL OF BIOFRONTERA AG.  Full Article

Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - BIOFRONTERA AG ::PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT.OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY.OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ.  Full Article

Biofrontera Prelim FY 2017 Revenue Expected In Range Of EUR 12.0-12.2 Mln
Monday, 22 Jan 2018 

Jan 22 (Reuters) - BIOFRONTERA AG ::PRELIM UNAUDITED FULL YEAR 2017 REVENUE IS EXPECTED TO BE IN RANGE OF EUR12.0 TO EUR12.2 MILLION.  Full Article

German stocks - Factors to watch on May 31

BERLIN, May 31 The following are some of the factors that may move German stocks on Thursday, which is a public holiday in parts of the country: